Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.

Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.

Item
http://www.wikidata.org/entity/Q37460276
Management of borderline resectable pancreatic cancerThe number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomyDose escalation with a vessel boost in pancreatic adenocarcinoma treated with neoadjuvant chemoradiation.A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinomaIdentification of an N staging system that predicts oncologic outcome in resected left-sided pancreatic cancerUpdated therapeutic outcome for patients with periampullary and pancreatic cancer related to recent translational research.The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative TherapyPreoperative neutrophil-to-lymphocyte ratio and tumor-related factors to predict lymph node metastasis in patients with pancreatic ductal adenocarcinoma (PDAC)Individualized radiotherapy (iRT) concepts for locally advanced pancreatic cancer (LAPC): indications and prognostic factors.Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater.Outcomes after extended pancreatectomy in patients with borderline resectable and locally advanced pancreatic cancer.Prognostic Significance of New AJCC Tumor Stage in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Therapy.Validation of a Proposed Tumor Regression Grading Scheme for Pancreatic Ductal Adenocarcinoma After Neoadjuvant Therapy as a Prognostic Indicator for Survival.Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.Should Fear of Adverse Events Influence the Decision to Administer Preoperative Therapy to Patients with Pancreatic Cancer?Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy.Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer.
P2860

Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.

Item
http://www.wikidata.org/entity/Q37460276
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 October 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neoadjuvant therapy is associa ...... resectable pancreatic cancer.
@en
Neoadjuvant therapy is associa ...... resectable pancreatic cancer.
@nl
type
label
Neoadjuvant therapy is associa ...... resectable pancreatic cancer.
@en
Neoadjuvant therapy is associa ...... resectable pancreatic cancer.
@nl
prefLabel
Neoadjuvant therapy is associa ...... resectable pancreatic cancer.
@en
Neoadjuvant therapy is associa ...... resectable pancreatic cancer.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P932
P356
P1433
P1476
Neoadjuvant therapy is associa ...... resectable pancreatic cancer.
@en
P2093
P2860
P2888
P304
P31
P356
P433
P478
P577
P6179
P698
P921
P932